Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib study of Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2 positive advanced gastric cancer

Next Previous
Search
Trial Profile

A phase Ib study of Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2 positive advanced gastric cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Adverse reactions
  • Acronyms Ni-HIGH study

Most Recent Events

  • 24 Oct 2023 Results (n=21) analyzing Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer, presented at the 48th European Society for Medical Oncology Congress
  • 24 Oct 2023 Results (n=23) assessing APC mutation MYC, and GATA6 amplifications association with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab and nivolumab presented at the 48th European Society for Medical Oncology Congress
  • 24 Oct 2023 Results assessing the clinical significance of ERBB2 amplification and TMB-H for T-mab plus N-mab with S-1/Capecitabine plus oxaliplatin new combination therapy, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top